At univariate analysis, severe steatosis (S3) (OR 3.5, 95% CI 1.3–9.3, p = 0.01) and more extensive IBD (OR 3.2, 95% CI 1.2–8.1, p = 0.02) were risk factors for increased AST/ALT, while the ongoing therapy with anti-Tumor Necrosis Factor alpha (antiTNFɑ) antibodies showed a protective effect (OR 0.2, 95% CI 0–0–8, p = 0.03). Here, GPT is linked to inflammatory bowel disease.